Published in J Clin Oncol on May 09, 2011
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 2.27
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging (2013) 2.06
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging (2014) 1.92
Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res (2015) 1.91
Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 1.54
Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging (2015) 1.41
Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics (2012) 1.33
Pretargeted molecular imaging and radioimmunotherapy. Theranostics (2012) 1.31
Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2012) 1.25
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol (2013) 1.19
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology (2016) 1.09
Comment on Campana et al.: radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging (2013) 1.07
Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front Endocrinol (Lausanne) (2012) 1.04
Targeting GRPR in urological cancers--from basic research to clinical application. Nat Rev Urol (2013) 1.01
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging (2014) 0.95
Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging (2014) 0.95
Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. Theranostics (2012) 0.94
Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2014) 0.94
Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors. Biomed Res Int (2013) 0.91
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging (2013) 0.90
A new era for the systemic therapy of neuroendocrine tumors. Oncologist (2012) 0.89
Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). Theranostics (2012) 0.88
Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging (2012) 0.87
Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol (2015) 0.87
Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer (2013) 0.85
Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging (2015) 0.84
Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis (2015) 0.83
Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol (2015) 0.83
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging (2014) 0.83
Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy. Am J Nucl Med Mol Imaging (2015) 0.83
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2014) 0.83
A review of the use of somatostatin analogs in oncology. Onco Targets Ther (2013) 0.83
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med (2013) 0.83
Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol (2015) 0.82
Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med (2014) 0.82
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging (2014) 0.82
Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging (2016) 0.81
Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. Eur J Nucl Med Mol Imaging (2013) 0.81
Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized? Eur J Nucl Med Mol Imaging (2013) 0.80
Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol (2012) 0.80
Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. Int J Mol Sci (2017) 0.80
Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol (2016) 0.79
Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Phys (2015) 0.79
Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int (2015) 0.79
Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging (2017) 0.79
Radiolabelled somatostatin analogue treatment in a case of carcinoid tumour with choroidal metastases. Eye (Lond) (2012) 0.79
Towards tailored radiopeptide therapy. Eur J Nucl Med Mol Imaging (2015) 0.79
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Res (2014) 0.79
[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics (2016) 0.78
Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol (2013) 0.78
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy. EJNMMI Res (2014) 0.78
Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbecks Arch Surg (2015) 0.77
Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept (2013) 0.77
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget (2016) 0.77
Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. Am J Nucl Med Mol Imaging (2013) 0.77
Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging (2015) 0.77
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. Am J Nucl Med Mol Imaging (2014) 0.77
How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective. Eur J Nucl Med Mol Imaging (2014) 0.77
Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths. Eur J Nucl Med Mol Imaging (2014) 0.77
Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? Eur J Nucl Med Mol Imaging (2015) 0.76
Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET. Theranostics (2016) 0.76
The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. Eur J Nucl Med Mol Imaging (2016) 0.76
Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol (2016) 0.75
Targeted therapies: Radiopeptide therapy improves outcomes for neuroendocrine cancers. Nat Rev Clin Oncol (2011) 0.75
Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol (2016) 0.75
Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol (2016) 0.75
The difference between medicine and magic is that magicians know what they are doing. Eur J Nucl Med Mol Imaging (2015) 0.75
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther (2017) 0.75
Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model. Theranostics (2016) 0.75
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res (2014) 0.75
High clinical and morphologic response using (90)Y-DOTA-octreotate sequenced with (177)Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2016) 0.75
Therapy: Neuroendocrine cancer--are two radionuclides better than one? Nat Rev Endocrinol (2012) 0.75
Radionuclide therapy beyond radioiodine. Wien Med Wochenschr (2012) 0.75
Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB (Oxford) (2013) 0.75
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al. Eur J Nucl Med Mol Imaging (2014) 0.75
Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity. Arch Immunol Ther Exp (Warsz) (2014) 0.75
Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy. EJNMMI Res (2016) 0.75
THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms. Ann Transl Med (2014) 0.75
Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. PET Clin (2015) 0.75
Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemp Oncol (Pozn) (2017) 0.75
Low Grade Neuroendocrine Tumors of the Lung. Front Oncol (2017) 0.75
Hypocalcaemia after treatment with [177Lu-DOTA 0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging (2013) 0.75
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. Eur J Nucl Med Mol Imaging (2014) 0.75
Randomized trials stopped early for benefit: a systematic review. JAMA (2005) 8.43
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med (2004) 6.55
Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med (2015) 6.06
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 5.08
Heat effects on mortality in 15 European cities. Epidemiology (2008) 4.63
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J (2006) 4.38
N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med (2002) 4.33
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA (2013) 4.33
One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med (2012) 4.24
Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med (2006) 4.19
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ (2010) 3.54
Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice. Arch Intern Med (2003) 3.42
Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med (2011) 2.97
Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 2.95
Reduced exposure to PM10 and attenuated age-related decline in lung function. N Engl J Med (2007) 2.86
Development of Land Use Regression models for PM(2.5), PM(2.5) absorbance, PM(10) and PM(coarse) in 20 European study areas; results of the ESCAPE project. Environ Sci Technol (2012) 2.84
Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med (2006) 2.84
High temperature and hospitalizations for cardiovascular and respiratory causes in 12 European cities. Am J Respir Crit Care Med (2008) 2.81
Cognitive training in Parkinson disease: cognition-specific vs nonspecific computer training. Neurology (2014) 2.74
Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol (2011) 2.69
Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ (2012) 2.69
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med (2005) 2.55
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev (2012) 2.31
Estimating the exposure-response relationships between particulate matter and mortality within the APHEA multicity project. Environ Health Perspect (2005) 2.25
Systematic reviewers neglect bias that results from trials stopped early for benefit. J Clin Epidemiol (2007) 2.20
Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol (2008) 2.18
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med (2006) 2.15
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health (2013) 2.12
Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ (2007) 2.07
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol (2012) 2.00
Nonconventional initiation complex assembly by STAT and NF-kappaB transcription factors regulates nitric oxide synthase expression. Immunity (2010) 1.90
STATs dimerize in the absence of phosphorylation. J Biol Chem (2003) 1.89
Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med (2011) 1.87
Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ (2012) 1.85
The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction. Eur Heart J (2007) 1.85
Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev (2011) 1.82
Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis. Crit Care Med (2010) 1.78
Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A. J Clin Invest (2009) 1.77
Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. Eur Heart J (2012) 1.73
Occupational exposure to dusts, gases, and fumes and incidence of chronic obstructive pulmonary disease in the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. Am J Respir Crit Care Med (2012) 1.73
Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis (2012) 1.67
Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med (2010) 1.67
Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol (2010) 1.66
NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. J Clin Invest (2006) 1.61
Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991-2003: methods and characterization of participants. Soz Praventivmed (2005) 1.55
STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog (2011) 1.54
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol (2012) 1.54
Short-term effects of air pollution on total and cardiovascular mortality: the confounding effect of influenza epidemics. Epidemiology (2005) 1.54
Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe (2010) 1.53
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol (2010) 1.53
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A (2006) 1.52
Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol (2011) 1.51
The Clinical Effectiveness of Pneumococcal Conjugate Vaccines. Dtsch Arztebl Int (2016) 1.49
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol (2003) 1.49
Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med (2015) 1.48
Initial experience with the Glidesheath Slender for transradial coronary angiography and intervention: a feasibility study with prospective radial ultrasound follow-up. Catheter Cardiovasc Interv (2013) 1.48
Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One (2012) 1.48
Heat wave 2003 and mortality in Switzerland. Swiss Med Wkly (2005) 1.47
The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging (2005) 1.47
Regulation of Stat3 nuclear export. J Clin Invest (2003) 1.46
Impact of road traffic noise annoyance on health-related quality of life: results from a population-based study. Qual Life Res (2010) 1.46
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging (2003) 1.46
Transportation noise and blood pressure in a population-based sample of adults. Environ Health Perspect (2011) 1.45
Heart rate variability in association with frequent use of household sprays and scented products in SAPALDIA. Environ Health Perspect (2012) 1.42
Living near main streets and respiratory symptoms in adults: the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults. Am J Epidemiol (2006) 1.41
Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers. Oncology (2011) 1.40
Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One (2013) 1.40
Effects of passive smoking on heart rate variability, heart rate and blood pressure: an observational study. Int J Epidemiol (2007) 1.40
Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev (2016) 1.38
Associations of daily walking activity with biomarkers related to cardiac distress in patients with chronic obstructive pulmonary disease. Respiration (2012) 1.38
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res (2007) 1.35
Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract. MBio (2011) 1.34
LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact. Trials (2009) 1.32
Combined single-photon emission computerized tomography and conventional computerized tomography (SPECT/CT): clinical value for the knee surgeons? Knee Surg Sports Traumatol Arthrosc (2009) 1.31
Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med (2008) 1.29
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci (2011) 1.27
Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med (2010) 1.27
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A (2009) 1.26
Influence of a lifestyle intervention in preschool children on physiological and psychological parameters (Ballabeina): study design of a cluster randomized controlled trial. BMC Public Health (2009) 1.26
A novel standardized algorithm for evaluating patients with painful total knee arthroplasty using combined single photon emission tomography and conventional computerized tomography. Knee Surg Sports Traumatol Arthrosc (2010) 1.26
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol (2003) 1.25
Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med (2005) 1.25
Association between ambient air pollution and diabetes mellitus in Europe and North America: systematic review and meta-analysis. Environ Health Perspect (2015) 1.24
The pylorus: take it or leave it? Systematic review and meta-analysis of pylorus-preserving versus standard whipple pancreaticoduodenectomy for pancreatic or periampullary cancer. Ann Surg Oncol (2007) 1.24
Meta-analyses: what they can and cannot do. Swiss Med Wkly (2012) 1.23